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FK 506 in the Management of Transplant-Related Nephrotic Syndrome 
and Steroid-Resistant Nephrotic Syndrome 
J. McCauley, A. Shapiro, V. Scantlebury, N. Gilboa, M. Jordan, C. Jensen, A. Naik, A. Tzakis, D. Ellis, 
and T. E. Starzl 
N EPHROTIC syndrome is a broad group of disorders 
with diverse etiologies. In common. all have pro-
teinuria. edema. hypercholesterolemia. and hypoalbumin-
emia. Steroids have proven effective in some histologic 
groups. but many are resistant to steroids and progress to 
end-stage renal disease. Transplant glomerulopathy and 
chronic rejection also contribute heavily to renal trans-
plant-related nephrotic syndrome. Previous studies with 
cyclosporine (Cy A) 1.2 and FK 5063 suggest that the clinical 
manifestations of nephrotic syndrome may be controlled 
with these agents. in native kidneys and in renal allografts. 
FK 506 is a potent macrolide immunosuppressant agent. 
which has proven effective in transplantation of the liver, 
kidney, and heart.4-6 We have previously reported suc-
cessful treatment of two patients with steroid-resistant 
nephrotic syndrome with FK 506.3 We report. herein. our 
preliminary experience treating steroid-resistant nephrotic 
syndrome and nephrotic syndrome after transplantation 
with FK 506. 
CASE MATERIAL 
Native Kidney Disease 
Seven patients with nephrotic syndrome. who had proved 
to be resistant to steroid therapy, were enrolled. The 
patients' ages ranged from 2.5 to 40 years. Three patients 
had failed CyA therapy in addition to having been nonre-
sponsive to other therapies. Four patients had focal seg-
mental sclerosis (FSGS). one had mesangial proliferative 
glomerulonephritis (GN) due to hepatitis B. one had mem-
branoproliferative GN (MPGN). and 1 had membranous 
GN. 
Transplanted Kidneys 
Seventeen patients with nephrotic syndrome after renal 
transplantation were converted from CyA to FK 506 in an 
attempt to correct the clinical manifestations of the ne-
phrotic syndrome. Graft biopsies were obtained on all 
patients prior to entry into this study. Based upon the 
allograft biopsies. the patients could be divided into those 
with chronic rejection (eight patients) and those with other 
histologic findings (nine patientsl: 
METHODS 
Patients with steroid-resistant nephrotic syndrome were uni-
formly treated with an FK 506 starting dose of 0.15 mglkg. twice 
a day. orally. Patients without active rejection and long-standing 
allografts were started on the lower doses. All other immunosup-
pressant agents were discontinued prior to starting FK 506. Later. 
FK 506 was tapered to the minimal dose required to control the 
proteinuria. Preexisting prednisone was tapered and withdrawn in 
most patients. All patients were treated with acyclovir and bac-
terium prophylaxis. 
RESULTS 
Native Kidneys 
Three of the seven patients rapidly responded to FK 506 
therapy, reducing proteinuria 600 mg/d or less within 2 
months. Mean pretreatment values were 4400 ± 3500 
mg/d. Two pediatric patients had FSGS and an adult had 
mesangial proliferative GN. One child had previously 
failed CyA, cytoxan. and steroids. Remission has been 
maintained for greater than 1 year in two of the three 
patients. Three additional patients decreased protein ex-
cretion by at least 50% after starting FK 506. Mean 
pretreatment protein excretion was 13.900 ± 11.300 mg/d. 
Only one patient was classified as a failure. Although 
protein excretion decreased by approximately 50%. this 
was not sustained. This patient. with FSGS. had failed 
high-dose steroids. chlorambucil. and CyA therapy. After 
stopping FK 506. a trial of cytoxan therapy was attempted 
without success. 
Creatinine clearance decreased in all patients after initi-
ating FK 506. but tended to improve as the dose was 
reduced. Two patients temporarily stopped taking FK 506. 
Both noted a prompt return of nephrotic syndrome within 
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NEPHROTIC SYNDROME 
Table 1. Transplant Glomerulopathy: Patient Demographics 
Patient Age Native Disease Transplant Bx 
JP 49 PCKD FSGS (prolif. GN) 
WO 46 Hypertension FSGS (mild ACR) 
EL 59 FSGS FSGS 
AM 24 SLE Mesangial Exp. 
PM 14 CGN FSGS 
AP 47 Diabetes FSGS 
AT 18 FSGS FSGS 
RW 5 FSGN FSGS 
GO 50 CGN Tx glom/chronic rej. 
days. The nephrotic syndrome was rapidly controlled 
when the drug was reinstituted. 
Transplanted Kidneys 
Patients Without Chronic Rejection. There were nine 
patients without chronic rejection on pretreatment biop-
sies. The demographic and histologic characteristics of 
these biopsied kidneys are displayed in Table I. FSGS was 
the most common finding in allograft biopsies. In two cases 
the FSGS was de novo. One patient had both transplant 
glomerulopathy and early chronic rejection. 
Six ofthe nine patients (66.6%) decreased proteinuria by 
50% or greater and had resolution of the signs of protein-
uria. Table 2 summarizes the response to FK 506. The 
response to FK 506 was dramatic in some patients. as 
illustrated by our first patient, IP (Fig 1). Although the 
response was usually rapid, a progressive decline in pro-
teinuria, over many months, was also seen. Our second 
patient (WD) initially experienced an increase in protein-
uria. followed by a slow progressive decline without a 
reduction in renal function (Fig 2). Two patients (AT. Rw) 
failed FK 506 therapy. Both had FSGS which had recurred 
within weeks of transplantation. and were referred prior to 
nephrectomy for intractable nephrotic syndrome. Both 
patients experienced an increase in proteinuria after con-
version to FK 506. The allograft has been removed in one 
patient (AT). 
Table 2. Transplant·Related Nephrotic Syndrome 
seR Proteinuria 
FlU 
Pre Post Pre Post (Monllls) 
JP 1.4 0.9 9766 284 16 
WD 1.2 1.1 5400 792 13 
EL 1.7 1.9 10,366 3172 9 
AM 1.5 1.3 2844 1856 5 
PM 1.6 2.6 9620 1309 12 
AP 1.9 2.0 3323 1763 2 
AT 2.4 3.5 9600 12.155 3' 
RW 1.3 2.7 8600 16,000 6' 
GO 1.4 1.1 4400 5400 1.5 
'Failed. 
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Fig 1. Rapid reduction in protein excretion after conversion to FK 
506 without significant increase in SCr (patient 1). 
Patients With Chronic Rejection. Patients with chronic 
rejection experienced little benefit from FK 506. At latest 
follow-up. four of the eight patients have had nephrecto-
mies or have started dialysis. Three patients have poorly 
functioning grafts with persistent nephrotic range protein-
uria in two. One patient died of an intracerebral hemor-
rhage unrelated to nephrotic syndrome. 
DISCUSSION 
FK 506 appears to be an effective treatment for some 
patients with steroid-resistant nephrotic syndrome and 
transplant-related nephrotic syndrome. It is likely that FK 
506 causes a functional change in the basement membrane 
and not a permanent change in the primary immunological 
origin of glomerulonephritis. since recurrence of nephrotic 
syndrome was rapid with drug withdrawal. A similar 
response has been noted in trials with CyA.1.2 FK 506 was, 
interestingly, effective in patients who had previously 
failed CyA therapy. 
Patients with nephrotic syndrome after transplantation 
have previously been susceptible to no therapy. Our 
preliminary experience suggests that FK 506 may be 
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Fig 2, Early exacerbation of proteinuria followed by progressive 
improvement (patient 2). 
